

To: michael.g.bird@exxonmobil.com <michael.g.bird@exxonmobil.com>
From: Bruce Jarnot <jarnotb@api.org>
Cc: Patrick Beatty (E-mail) <patrickbeatty@chevrontexaco.com>; Cagen, Stuart Z SCC-CF-SS <stuart.cagen@shell.com>
Bcc:
Received Date: 2004-11-30 14:08:40 GMT
Subject: BHRC-TC... Exposure Assessment Review at EMBSI

G'morning Michael -

Thanks very much for taking the lead on the Technical Committee's review of Exposure Assessment (EA) progress in the CC, DP & ME Shanghai Health Studies.

Patrick & Stuart are presently working logistics for this EA review, and for a proposed meeting with Rich Irons to review budget reanalyses, before the next OC meeting at API on December 16th.

It's still unclear whether the TC can meet face-to-face for either or both of these review sessions, or whether we will have better luck coordinating schedules by way of conference calls. In either case, I'll keep you informed as "EA Host" on any developments throughout this week.

Best Regards - Bruce.

-----Original Message-----

From: michael.g.bird@exxonmobil.com
[mailto:michael.g.bird@exxonmobil.com]
Sent: Sunday, November 21, 2004 11:53 AM
To: Beatty, Patrick (PatrickBeatty); szcagen@Shell.Com
Cc: Bruce Jarnot
Subject: RE: BHRC Technical committee

On Friday afternoon (11/19), I sat in on a review by EMBSI management of the EMBSI contract/involvement in the SHS. There were few issues identified that as a Tech Committee member I was not aware, however I came away with a much greater appreciation of the EA aspects of the study and operational aspects which impact other study components and in particular gained insight as to the needs and benefits of achieving quantitative exposure assessment for the DP and CC. Also the current lack of success of obtaining bone marrow for ME 2B and likely reasons for this. I think the BHRC Tech Committee would benefit from hearing this directly from Tom, Yimei and Rob. Richard Irons tends to represent and focus on the lab /clinical aspects - that's his expertise after all - but with the above EA input, I think the Tech Committee will do a much better assessment of what can be achieved, and \$\$'s needed, based on the 2 years of study experience.

I recommend that we have a conference call (or meeting) with the EA team additional to any visit to Denver and to do this, as soon as possible and before the next Oversight committee on December 12th. My intent is not to exclude Irons as PI - he could participate too - but I believe that our time as a committee focussing on the EA aspect (eg impact on the CC study) with the EA team would be enormously valuable, would provide a better basis for further discussions with the PI's, and for meeting the Oversight committee's expectations.

Please call if you want to discuss further or if I can help in convening the above.

Michael

Michael G. Bird, PhD., DABT
Toxicology & Environmental Sciences Division,
ExxonMobil Biomedical Sciences, Inc.
1545 Route 22 East
P.O. Box 971
Annandale, New Jersey 08801-0971
tel: 908 730 1060
fax: 908 730 1199
Email: michael.g.bird@exxonmobil.com
